111 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
and Governance (“ESG”) initiatives as long-term value drivers for the Company and our stockholders. Our focus on, and commitment to ESG initiatives … and whether its leadership structure is appropriate to effectively address the specific needs of our business and the long-term interests of our stockholders
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
Executive Officer of Larimar. “Additionally, the first patient in our OLE study has been dosed. The OLE study will inform on the long-term safety profile … and long-term tissue frataxin levels. We remain on track to report interim data from the OLE study in the fourth quarter of 2024.”
Dr. Ben-Maimon
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
11 Mar 24
Other Events
4:09pm
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s … Ataxia
Study will inform on long-term safety profile and tissue frataxin levels
OLE initiated with 25 mg daily subcutaneous injections
8-K
EX-99.2
8cf3z8008md
11 Mar 24
Other Events
4:09pm
8-K
EX-99.3
ltb77
11 Mar 24
Other Events
4:09pm
8-K
EX-1.1
j48y3
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
a887 51jeu91
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
0l2iwwl v0x07u44ij
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
4oxy94qnw
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.3
c7ms6fpl ur
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
scwakz
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
fe4 p2lmd5k7j
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.2
b7c69
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
3vlrk8yfbis y73
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
s53yvl6
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
EX-99.1
z0r05
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.2
d0tkz4tpsnfru7rf
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am